Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Teucrium Soybean Fund — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Teucrium Soybean Fund trades at $27.2 (market cap $43.28M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 66.1× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Teucrium Soybean Fund for 25 Days on average.
| DYN | SOYB | |
|---|---|---|
Market Cap | $2.86B | $43.28M |
Volume | 3,341,579 | 28,719 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $26.78 | $28.14 |
52-Week Low | $14.60 | $21.59 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SOYB trades at $27.33, down 0.51% today, with a bullish technical signal driven by moving averages. The stock is consolidating near key support at $27, with neutral oscillators indicating limited momentum. Recent news highlights potential catalysts from U.S.-China trade talks, which could boost soybean demand.
The outlook hinges on trade developments and commodity price trends, offering upside if diplomatic progress materializes. Risks include geopolitical tensions and commodity market volatility. Analyst sentiment appears cautiously optimistic, but fundamental data remains sparse for detailed assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
